Literature DB >> 24173041

Novel immunomodulatory approaches for the management of multiple sclerosis.

O H Kantarci1, I Pirko1, M Rodriguez2.   

Abstract

We provide a focused review of novel immunomodulatory approaches for the treatment of multiple sclerosis, the most common acquired inflammatory demyelinating disease of humans. The requirement for such a review was stimulated by the emerging application of novel oral medications and the need for the practicing physician to place these within the treatment paradigm. We provide a conceptual diagram of our current view of the pathogenesis of demyelination and remyelination in this disorder. In addition, we include a working template on how to use a tier 1 and tier 2 approach to medications as the disease worsens in the individual. We emphasize the approach of treatment based on "individualized medicine," tailored to the specific needs of each patient. In the future, we envision new drugs to enhance remyelination and protect neurons and axons from death in order to promote central nervous system regeneration and repair.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24173041     DOI: 10.1038/clpt.2013.196

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis.

Authors:  J H Simon; R A Bermel; R A Rudick
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-03       Impact factor: 3.825

2.  Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells.

Authors:  Melanie Korsen; Sara Bragado Alonso; Lizzy Peix; Barbara M Bröker; Alexander Dressel
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

3.  Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.

Authors:  Barbara H Johnson; Machaon M Bonafede; Crystal Watson
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

Review 4.  Effects of chalcone derivatives on players of the immune system.

Authors:  Jian Sian Lee; Syed Nasir Abbas Bukhari; Norsyahida Mohd Fauzi
Journal:  Drug Des Devel Ther       Date:  2015-08-19       Impact factor: 4.162

5.  Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up.

Authors:  Marja-Liisa Sumelahti; Markus H A Holmberg; Annukka Murtonen; Heini Huhtala; Irina Elovaara
Journal:  Mult Scler Int       Date:  2014-11-09

6.  A common gene expression signature in Huntington's disease patient brain regions.

Authors:  Andreas Neueder; Gillian P Bates
Journal:  BMC Med Genomics       Date:  2014-10-30       Impact factor: 3.063

7.  Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database.

Authors:  Aaron Boster; Jacqueline Nicholas; Ning Wu; Wei-Shi Yeh; Monica Fay; Michael Edwards; Ming-Yi Huang; Andrew Lee
Journal:  Neurol Ther       Date:  2017-02-16

8.  Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data.

Authors:  Jacqueline Nicholas; Aaron Boster; Ning Wu; Wei-Shi Yeh; Monica Fay; Jon Kendter; Ming-Yi Huang; Andrew Lee
Journal:  Pharmacoecon Open       Date:  2018-03

9.  An Assay that Predicts In Vivo Efficacy for DNA Aptamers that Stimulate Remyelination in a Mouse Model of Multiple Sclerosis.

Authors:  Robin M Heider; John A Smestad; Hernan Nicolas Lemus; Brandon Wilbanks; Arthur E Warrington; Justin P Peters; Moses Rodriguez; L James Maher
Journal:  Mol Ther Methods Clin Dev       Date:  2018-03-21       Impact factor: 6.698

10.  Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.

Authors:  Johannes Ehler; Sebastian Koball; Martin Sauer; Steffen Mitzner; Heiko Hickstein; Reiner Benecke; Uwe K Zettl
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.